



CLAIMS AMENDMENTS

Please cancel Claims 1-41, 44-61, 64, 66-72 and 74-90, which are withdrawn from consideration, without prejudice.

Please amend the claims as follow:

Claims 1-41 (cancelled)

42. (currently amended) A pharmaceutical composition comprising a an isolated human monoclonal antibody selected from the group consisting of mAb sHIgM22 (LYM 22), ~~sHIgM46 (LYM46), ebvHIgM MSH19D10, Cb2BG8, MSH10E10~~, mixtures thereof, monomers thereof, active fragments thereof capable of binding oligodendrocytes, ~~binding partners thereto~~, and recombinant antibodies derived therefrom and a pharmaceutically acceptable carrier, vehicle or diluent.

43. (currently amended) A pharmaceutical composition comprising isolated mAb SHIgM22 (LYM22) and a pharmaceutically acceptable carrier, vehicle or diluent.

Claim 44 (cancelled)

Claim 45 (cancelled)

Claim 46 (cancelled)

Claim 47 (cancelled)

Claim 48 (cancelled)

Claim 49 (cancelled)

Claim 50 (cancelled)

Claim 51 (cancelled)

Claim 52 (cancelled)

Claim 53 (cancelled)

Claim 54 (cancelled)



Claim 55 (cancelled)

Claim 56 (cancelled)

Claim 57 (cancelled)

Claim 58 (cancelled)

Claim 59 (cancelled)

Claim 60 (cancelled)

Claim 61 (cancelled)

62. (currently amended) An isolated antibody produced by injecting a substantially immunocompetent host with an antibody-producing effective amount of an antibody peptide, and harvesting said antibody, said antibody peptide comprising an amino acid sequence selected from the group consisting of an amino acid sequence set out in FIGURE 35 (SEQ ID NO: 8; 7), FIGURE 36 (SEQ ID NO: 10; 9), ~~FIGURE 71 (SEQ ID NO: 49), FIGURE 72 (SEQ ID NO: 51)~~ and active fragments thereof, said active fragments capable of binding oligodendrocytes.

63. (currently amended) The isolated antibody of Claim 62 which is monoclonal.

Claim 64 (cancelled)

65. (currently amended) The isolated antibody of Claim 62 which is a bispecific or chimeric antibody. ~~chimeric (bi-specific).~~

Claim 66 (cancelled)

Claim 67 (cancelled)

Claim 68 (cancelled)

Claim 69 (cancelled)

Claim 70 (cancelled)

Claim 71 (cancelled)

Claim 72 (cancelled)

73. (currently amended) A pharmaceutical composition comprising an amount of an isolated the polypeptide of ~~Claim 72~~ produced by the method of

(a) introducing a vector comprising a DNA molecule comprising a DNA sequence encoding an antibody polypeptide selected from:

(i) the DNA sequence encoding a polypeptide having a sequence comprising the amino acid sequence set out in FIGURE 35 (SEQ ID NO:7); and

(ii) the DNA sequence encoding a polypeptide having a sequence comprising the amino acid sequence set out in FIGURE 36 (SEQ ID NO:9);

into a suitable host cell;

(b) culturing the resulting host cell so as to produce the polypeptide;

(c) recovering the polypeptide produced in step (b); and

(d) purifying the polypeptide recovered in step (c);

and a pharmaceutically acceptable carrier, vehicle or diluent.

Claim 74 (cancelled)

Claim 75 (cancelled)

Claim 76 (cancelled)

Claim 77 (cancelled)

Claim 78 (cancelled)

Claim 79 (cancelled)

Claim 80 (cancelled)

Claim 81 (cancelled)

Claim 82 (cancelled)

Claim 83 (cancelled)

Claim 84 (cancelled)

Claim 85 (cancelled)

Claim 86 (cancelled)

Claim 87 (cancelled)

Claim 88 (cancelled)

Claim 89 (cancelled)

Claim 90 (cancelled)

91. (new) An isolated antibody comprising an amino acid sequence set out in FIGURE 35 (SEQ ID NO:7), FIGURE 36 (SEQ ID NO:9), or active fragments thereof capable of binding oligodendrocytes.

92. (new) An isolated antibody comprising a heavy chain variable region sequence as set out in FIGURE 35 (SEQ ID NO:7).

93. (new) An isolated antibody comprising a light chain variable region sequence as set out in FIGURE 36 (SEQ ID NO:9).